Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and death

H Tatsukawa1,3, Y Furutani2,3, K Hitomi1 and S Kojima*2

Transglutaminase 2 (TG2) is primarily known as the most ubiquitously expressed member of the transglutaminase family with Ca2+-dependent protein crosslinking activity; however, this enzyme exhibits multiple additional functions through GTPase, cell adhesion, protein disulfide isomerase, kinase, and scaffold activities and is associated with cell growth, differentiation, and apoptosis. TG2 is found in the extracellular matrix, plasma membrane, cytosol, mitochondria, recycling endosomes, and nucleus, and its subcellular localization is an important determinant of its function. Depending upon the cell type and stimuli, TG2 changes its subcellular localization and biological activities, playing both anti- and pro-apoptotic roles. Increasing evidence indicates that the GTP-bound form of the enzyme (in its closed form) protects cells from apoptosis but that the transamidation activity of TG2 (in its open form) participates in both facilitating and inhibiting apoptosis. A difficulty in the study and understanding of this enigmatic protein is that opposing effects have been reported regarding its roles in the same physiological and/or pathological systems. These include neuroprotective or neurodegenerative effects, hepatic cell growth-promoting or hepatic cell death-inducing effects, exacerbating or having no effect on liver fibrosis, and anti- and pro-apoptotic effects on cancer cells. The reasons for these discrepancies have been ascribed to TG2’s multifunctional activities, genetic variants, conformational changes induced by the immediate environment, and differences in the genetic background of the mice used in each of the experiments. In this article, we first report that TG2 has opposing roles like the protagonist in the novel Dr. Jekyll and Mr. Hyde, followed by a summary of the controversies reported, and finally discuss the possible reasons for these discrepancies.

Cell Death and Disease (2016) 7, e2244; doi:10.1038/cddis.2016.150; published online 2 June 2016

Facts

- Tissue transglutaminase (TG2) is a multifunctional enzyme that exhibits crosslinking, GTPase, cell adhesion, protein disulfide isomerase, kinase, and scaffold activities.
- By virtue of these multiple activities, TG2 is implicated in the regulation of cell growth, differentiation, and apoptosis.
- However, opposing effects have been reported regarding its roles even in the same physiological and pathological systems.
- To help understand these discrepancies, we summarize and discuss possible reasons for opposing effects in each case.

Open Questions

- How can we measure the individual activity of multiple functions of TG2 in vivo?
- How are these multiple functions and genetic variants of TG2 regulated?
- How is TG2’s substrate specificity (other than its sublocalization) determined?

Transglutaminase 2 (TG2) is a multifunctional enzyme and the most ubiquitously expressed member of the large TG family, a protein family of eight isozymes designated as blood coagulation factor XIII and TG1-7. TGs primarily deamidate γ-carboxamide groups of specific protein-bound glutamines while exchanging any primary amines, the ε-amino group of a lysine residue, or water, and form ammonia plus an N’(γ-glutamyl)lysine crosslinking between glutamine and lysine residues or convert glutamine to glutamic acid.1–3 TG2 exerts additional enzymatic activities that do not require Ca2+;1,3 that is, hydrolyzing ATP and GTP to mediate signal transduction through G-protein-coupled receptors,4,5 protein disulfide isomerase and protein kinase,6,7 interacting with several proteins as an adhesion or scaffold protein8 (Figure 1).

TG2 is predominantly found in the cytosol. TG2 also appears in the nucleus, mitochondria, plasma membrane, and extracellular matrix (ECM).9 In mammals, TG2 is widely

1Department of Basic Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Nagoya University, Nagoya 464-8601, Japan and 2Micro-Signaling Regulation Technology Unit, RIKEN Center for Life Science Technologies, 2-1 Hirosawa, Saitama 351-0198, Japan
*Corresponding author: S Kojima, Micro-Signaling Regulation Technology Unit, RIKEN Center for Life Science Technologies, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan. Tel. +81 48 467 7938; Fax +81 48 462 4675; E-mail: skojima@riken.jp
3These authors contributed equally to this work.

Abbreviations:  TG, Transglutaminase; ECM, Extracellular matrix; ER, Endoplasmic reticulum; FN, Fibronectin; NF-κB, Nuclear factor-kappa B; RA, Retinoic acid; RAR, Retinoic acid receptor; PDI, Protein disulfide isomerase; TGF-β, Transforming growth factor-β; ASH, Alcoholic steatohepatitis; NASH, Non-alcoholic steatohepatitis

Received 01.2.16; revised 28.4.16; accepted 28.4.16; Edited by GM Fimia
present throughout the body including blood, extracellular spaces, and intracellular compartments of nearly all tissues, and induces tissue remodeling/wound healing and ECM assembly as well as cell growth, differentiation, and cell death.\textsuperscript{10} TG2 is thus involved in the pathogenesis/treatment of cancer, diabetes, neurodegeneration, fibrosis, inflammatory, and autoimmune disorders\textsuperscript{2} as well as liver diseases.\textsuperscript{11–13} For the general functions and structure of TG2, including topics on genetically engineered mouse models and inherited disorders, refer to well-written review articles and/or a book recently released.\textsuperscript{2,9,14}

Opposing effects have been reported for the roles of TG2 in the same physiological and/or pathological systems due to differences in

1. The enzymatic and non-enzymatic activities or properties of TG2, that is, GTPase versus transamidation versus scaffold activities.\textsuperscript{2,15,16}

2. Genetic variants including alternative splicing, that is, the short or truncated form (TG2-S) versus the long form (TG2-L)\textsuperscript{17} and single-nucleotide polymorphisms.\textsuperscript{18}

3. The conformational structure (open versus closed forms), which is affected by immediate cellular and tissue environments.\textsuperscript{2,15}

4. The genetic background of mice.\textsuperscript{2,13}

The aim of this review is to summarize recently obtained knowledge of how TG2 plays Dr. Jekyll and Mr. Hyde (opposing roles) in the regulation of cell growth and death.

**Multifunctional Activities of TG2 and Its Regulation**

**GTPase.** Intracellular TG2 in its closed form acts as a Ca\textsuperscript{2+}-independent GTPase in normal cells when the intracellular Ca\textsuperscript{2+} concentration is as low as 10–20 nM, participating
in the transmembrane signaling of phospholipase C5 as a component of α₃-adrenergic receptor complexes and supporting the growth of hepatic cells. GTP binding with TG2 sustains the closed form and prevents its conformational change to the open form; the emergence of crosslinking activity is thus a result of binding to Ca²⁺, whereas the depletion of GTP causes conformational changes in the open form. In this scenario, the emergence of crosslinking activity induces apoptosis in islet β-cells and other cell types.

Transamidase. When cells are injured (or receive certain stimuli) and the intracellular Ca²⁺ concentration increases to more than 700–800 nM, TG2 markedly alters its structure and transforms into an open form that exerts crosslinking activity. In the specific conditions such as tissue regeneration and remodeling, TG2 crosslinks ECM proteins, however, despite a high extracellular Ca²⁺ concentration (in the mM range) outside of cells, TG2 usually does not exert transamidation but instead mediates multiple and complex regulatory interactions, particularly in the regulation of cell-ECM interactions and outside-in signaling via transmembrane receptors, indicating that Ca²⁺ and/or GTP concentrations are not the sole determinants of transamidation activity.

Integrin–fibronectin interaction. TG2 has been identified as an important extracellular crosslinking enzyme involved in ECM turnover. In contrast, TG2 is secreted into ECM and forms a hetero complex with its high-affinity binding partner fibronectin (FN) through its N-terminal 42-kD fragment in a crosslinking activity-independent manner. The TG–FN complex promotes FN fibril deposition and RGD-independent cell adhesion via syndecan-4/2 and α5β1 integrin co-signaling, and sustains cell survival in osteoblasts, bone marrow-derived mesenchymal stem cells, and many tumor cells.

Miscellaneous functions. Protein disulfide isomerase (PDI) activity has been implicated in mitochondrial-dependent apoptosis, whereas TG2 has been reported to exert an intrinsic serine/threonine kinase activity and to phosphorylate insulin-like growth factor (IGF)-binding protein-3 (IGFBP3), p53 tumor suppressor protein, H1-4 histones, and Rb protein. Moreover, TG2 affects the hypusination of eukaryotic initiation factor 5A (eIF5A) in BALB/c 3T3 cells; this action may be related to the fact that eIF5A serves as a binding protein and/or substrate for TG2.

Regulation. The gene expression related to TG2 is modulated by endoplasmic reticulum (ER) stress, tissue remodeling, inflammation, viral infection, and apoptotic signals. As well as cancers, TG2 has an important role in the neutrophil–granulocyte differentiation and gene expression of neutrophil’s cellular functions in addition to related adhesive, migratory, and phagocytic capacities. The transcriptional activation of the TG2 gene, TMG2, is mediated by nuclear factor-kappa B (NF-kB), RA receptor (RAR)/retinoid X receptor, liver X receptor/RAR, and Sp1. Two examples of a positive feedback loop are known to act in the regulation of TG2 expression. TG2 is dispensable for latent TGF-β activation in many tissues, and the generation of TGF-β may stimulate TG2 gene expression. TG2 activates NF-kB via the depletion of inhibitor of NF-κB (IκB) via polymerization in the absence of IκB kinase activation. This activity results in the dissociation of NF-κB and its translocation to the nucleus, where it may upregulate TG2 in cancer cells.

Ca²⁺ and nucleotides (GTP/ATP), respectively, act as the activator and suppressors of the transamidase activity of TG2. Nitric oxide (NO) is also a potent inhibitor by promoting S-nitrosylation on the active site C277. The decreased S-nitrosylation of TG2 contributes to age-related increases in vascular stiffness. Micro-RNA (miR-19) directly downregulates TG2 expression and enhances the invasion of colorectal cancer cells. Finally, the SUMOylation of TG2 enhances its toxicity.
protein levels and activity by blocking the ubiquitination of (and thus stabilizing) TG2 protein. 69

Opposing Roles of TG2 In Vitro

The accumulation of TG2 in various cell and tissue types undergoing apoptosis has been demonstrated, 70,71 elevated TG2 activity is correlated with enhanced apoptosis in a neuroblastoma cell line, 72 whereas treatment with antisense against TG2 reduces apoptosis. 73 When neuroblastoma cells are transfected with plasmid overexpressing TG2 but not mutated TG2 lacking crosslinking activity and then treated with staurosporine or osmotic stress, an increased crosslinking activity accompanies the activation of caspase-3 and apoptotic nuclear changes. 74 In mitochondria, interaction with Bax through TG2’s BH3 domain plus the predicted crosslinking of Bax causes mitochondrial depolarization, the release of cytochrome c, and cell death. 45 Nuclear TG2 causes caspase-independent cell death via the crosslinking and inactivation of the general transcription factor Sp1, resulting in the reduced expression of growth factor receptors, such as c-Met and EGF receptors, that are essential for cell survival. 12,75 In contrast, numerous reports have found a protective effect of TG2 in cell death induced by TNF-α, 76 RA, 77 and stressors such as thapsigargin, hyperosmotic stress, and oxygen/glucose deprivation. 78

Below are examples in which TG2 has Dr. Jekyll and Mr. Hyde (opposing roles; Tables 2,3,4,5,6).

Neuroprotective Versus Neurodegenerative Roles by Modulating HIF1 and Huntingtin Functions, Respectively

Increased activity and expression of TG2 are observed in the ischemic hippocampus after reperfusion (Table 2). 79,80 TG2 expression is induced by oxidative stress, and the induction of inducible NO synthase and NO production, which contribute to neurodegeneration, are closely associated with TG2 expression in the lipopolysaccharide-stimulated activation of astrocytes. 81 The infarct volume was smaller in both TG2 knockout mice and mice treated with cystamine than in control mice. 82 In contrast, both SH-SY5Y human neuroblastoma cells 83 and a permanent middle cerebral artery ligation stroke model 84 demonstrated that hypoxic conditions increased nuclear TG2, TG2 binding to HIF1β independently of transamidase activity, and the prevention of the upregulation of pro-apoptotic Bnip3 85 and Noxa, 86 thereby protecting neuronal cells from hypoxia-induced death in ischemia and stroke. 83,84

Increased TG2 levels and/or activity, especially the involvement of nuclear TG2, have been observed in many neurodegenerative diseases such as Alzheimer’s disease (AD), Huntington’s disease (HD), and Parkinson’s disease (PD). 87 AD is characterized by the formation of extracellular neurotoxic aggregates consisting of amyloid-β protein or intracellular neurotoxic aggregates consisting of hyperphosphorylated tau. TG2 mediates the crosslinking of both amyloid-β and tau in vitro 88,89 and the polyamination of the tau protein, resulting in an increased resistance of tau to proteolytic degradation by calpain. This change leads to higher levels of non-degradable tau within the neuron, 90 which indicates that TG2 may accelerate the aggregation process of amyloid-β and tau in AD patients. Furthermore, the enhanced expression of a short form of TG2 (sTG2), an alternatively spliced transcript lacking GTPase activity that maintains poor amidase activity, and the prevention of the upregulation of pro-apoptotic Bnip3 85 and Noxa, 86 thereby protecting neuronal cells from hypoxia-induced death in ischemia and stroke, 83,84

Increased TG2 levels and/or activity, especially the involvement of nuclear TG2, have been observed in many neurodegenerative diseases such as Alzheimer’s disease (AD), Huntington’s disease (HD), and Parkinson’s disease (PD). 87 AD is characterized by the formation of extracellular neurotoxic aggregates consisting of amyloid-β protein or intracellular neurotoxic aggregates consisting of hyperphosphorylated tau. TG2 mediates the crosslinking of both amyloid-β and tau in vitro 88,89 and the polyamination of the tau protein, resulting in an increased resistance of tau to proteolytic degradation by calpain. This change leads to higher levels of non-degradable tau within the neuron, 90 which indicates that TG2 may accelerate the aggregation process of amyloid-β and tau in AD patients. Furthermore, the enhanced expression of a short form of TG2 (sTG2), an alternatively spliced transcript lacking GTPase activity that maintains poor amidase activity, and the prevention of the upregulation of pro-apoptotic Bnip3 85 and Noxa, 86 thereby protecting neuronal cells from hypoxia-induced death in ischemia and stroke, 83,84

Table 2 Examples of opposing functions of TG2 in the brain

| Brain | Reports | Possible causation | References |
|-------|---------|-------------------|------------|
| Protective effect | Hypoxia-induced cell death in ischemic stroke | Cell proliferation of GTPase activity is enhanced by neuronal TG2 overexpression and nuclear localization. | 84 |
| Degenerative effect | Huntington’s disease in R6/1 transgenic mice | Genetic knockout or inhibitor of TG2 attenuates neurodegenerative disease regardless of whether TG2 is involved in the formation of polyglutamine. The open conformation of TG2 is toxic in cytosol, whereas the closed conformation of TG2 promotes survival in the nucleus. | 96,97,175,176 |
| | Polyglutamine disease in spinocerebellar ataxia-1 transgenic mice | | 177 |
| | Crosslinking of huntingtin with expanded polyglutamine, β-amyloid, tau, and α-synuclein in Huntington’s, Alzheimer’s, and Parkinson’s diseases | | 88,114,175,178,179 |
| | Cell death in ischemic stroke | | 82,180 |
| | Infarct volume in TG2−/− mice was reduced. Short form of TG2 | The short form of TG2 induces cell damage and death | 91 |

In the frontal cortex of postmortem HD brain tissues, 99% colocalization is observed between ε-(γ-glutamyl)lysine cross-links and huntingtin aggregates in the nucleus, 84 indicating an involvement of nuclear TG2 in HD. Furthermore, the TG inhibitors cystamine and monodansylcadaverine partially suppress aggregate formation and apoptosis in cells expressing truncated dentatorubral-pallidolysian atrophy protein with an expanded polyglutamine stretch. 95 Although, (i) the in vivo ablation of the TG2 gene ameliorates HD symptoms and leads to unaltered or even increased numbers of neuronal intranuclear inclusions, 96,97 which has recently been ascribed at least in part to a loss of TG2’s regulatory effect on autophagy, 98 (ii) cystamine inhibits not only TG2 but also caspase-3, 99 (iii) neuronal intranuclear inclusions are likely to be formed at a late stage of aggregation and do not directly affect the progression of pathogenesis; 100 and (iv) the genetic deletion or enzymatic inhibition of TG2 alleviates the degenerative process and improves survival as well as life span, 97,101

Cell Death and Disease
isolated polyglutamine forms aggregates through a β-sheet-based nucleation mechanism, indicating a causative role for nuclear TG2 in HD pathogenesis via mechanisms other than the formation of neuronal intranuclear inclusions.102

Transcription dysregulation and impaired energy homeostasis have important roles. The introduction of ZDON, a peptide inhibitor of TG2, ameliorates HD symptoms.101,103

The mutant huntingtin binds to and inactivates other polyglutamine-enriched proteins such as transcription factors, including the general transcription factor Sp1 or its coactivator TAFII130,104–106 which may repress the Sp1-dependent transcription of BDNF,107 dopamine D2 receptor,104,105 preproenkephalin,104 the mitochondrial proteins PGC-1α, and cytochrome c.108,109 These results imply that although nuclear TG2 is not essential for inducing HD, it may be an important factor in exaggerating HD symptoms through the transcriptional dysregulation of these survival factors and key metabolic genes. Defective nuclear actin remodeling causes faster cell death in correlation with disease progression.110

Cofilin is an actin binding protein that is required for actin treadmilling.111 The formation of the dynamic cytoskeleton, referred to as ‘actin-cofilin rods’, is a self-protecting reaction against cellular stress and is sustained by an association with normal huntingtin upon its release from the ER and localization to the nucleus under stress conditions. In response to cellular stress, delayed and aberrant actin-cofilin rods are formed in neurodegenerative disease by (i) mutant huntingtin via the impairment of the normal function of huntingtin and (ii) an excessive crosslinking of actin-cofilin complexes by stress-activated nuclear TG2.110 As stated above, TG2 binds

Table 3 Examples of opposing functions of TG2 in the liver

| Liver | Reports | Possible causation | References |
|-------|---------|--------------------|------------|
| Protective effect | Activation of Sp1 via its dimerization | Difference in cell types | 123, 20,128 |
| | CCI4 and Fas-induced liver injury | | |
| Promotive effect | CCI4-induced liver injury and fibrosis | Different animal backgrounds | 121, 11,12,136,137 |
| | Liver damage and injury in ASH/alcohol, NASH/FFAs | | |
| | Liver damage in NZB/W F1 mice (a well-known lupus-prone strain) | | |
| No effect | CCI4- or thioacetamide-induced liver fibrosis | | 141 |

Table 4 Examples of opposing functions of TG2 in cancer

| Cancer | Reports | Possible causation | References |
|--------|---------|--------------------|------------|
| Progressive effect | Increased drug resistance and metastasis in breast cancer cells | Different cell types | 33,142 |
| | Stabilization of adhesive interactions for metastasis in melanoma cells | Different cell types | 144 |
| | Anti-apoptotic effect in RA- or HPR-treated NIH3T3, HL-60, and embryonic lung fibroblast cells | Retention of Rb protein action | 150 |
| | Attenuated apoptosis in thapsigargin-treated HEK293 cells | Different chemopreventive agents and cell types | 151 |
| | TG2 enhances EGFR expression and transformation in glioblastomas | Interference with EGFR downregulation | 148 |
| Suppressive effect | Suppression of tumor progression and metastasis | Reduced metastatic activity via excess stabilization/accumulation of ECM crosslinking | 145,146 |
| | Chemoprevention by retinoid | Different chemopreventive agents and cell types | 75 |
| | Growth arrest/apoptosis in RA-treated U937 cells | Lost activity of Rb protein | 149, 37 |
| | Phosphorylation of Rb protein in MCF-7 | | |
| No effect | Cell growth/apoptosis in TG2-transfected fibrosarcoma cell | Different cell types | 146 |

Table 5 Examples of opposing functions of TG2 in the pancreas

| Pancreas | Reports | Possible causation | References |
|----------|---------|--------------------|------------|
| Promotive effect | Glucose-stimulated insulin release | Different functional activity of TG2 | 152–154,158,159 |
| | Insulin secretion induced by RA and Ca2+ | | 155,156 |
| No effect | Insulin secretion induced by either cAMP or the phorbol ester PMA | Different functional activity of TG2 | 157,160 |
| | Intrapertitoneal glucose tolerance tests and insulin tolerance tests | Different background of TG2 knockout mice | | Broad biological effects of TG inhibitors |
FN through its N-terminal domain and interacts with many other scaffold proteins such as integrins and lamin A and C.\textsuperscript{28,112,113} In PD patients’ brains, TG2 expression is increased in the substantia nigra, and TG2-catalyzed crosslinking has been shown to colocalize with α-synuclein, a substrate for TG2 \textit{in vivo},\textsuperscript{114} in dementia with Lewy bodies.\textsuperscript{115}

**Hepatic Protective Versus Insult Roles Through Sp1 Crosslinking**

TG2 crosslinking activity significantly increases with carbon tetrachloride (CCL\textsubscript{4}) or ethanol-induced liver injury in rats and in acute human liver injury (Table 3).\textsuperscript{116–120} Cystamine and garlic extract prevent CCL\textsubscript{4}-induced liver injury and fibrosis via the inhibition of TG2.\textsuperscript{121} Sp1 is a general transcription factor that is rich in lysine and glutamine residues,\textsuperscript{122} thereby serving as a good substrate for TG2 both \textit{in vitro} and \textit{in vivo}.\textsuperscript{12} An upregulation of Sp1’s transcriptional activation activity upon crosslinking with nuclear TG2 in human 293T cells likely occurred because Sp1 exerts higher transcriptional activation activity as a dimer or trimer,\textsuperscript{123,124} whereas in alcohol or free fatty acid (FFA)-treated hepatic cells, highly crosslinked, oligomerized Sp1 loses its transcriptional activation activity. A defect in Sp1 activity causes the decreased expression of c-Met, the major receptor for hepatocyte growth factor, leading to caspase-independent hepatic cell death in culture systems and animal models as well as in patients with both alcoholic steatohepatitis (ASH) and non-ASH (NASH).\textsuperscript{11,12,75} FFAs increase ER stress, NF-κB activation, and nuclear TG2 through a pancreatic ER kinase (PERK)-dependent pathway, whereas ethanol-induced nuclear TG2 is dependent at least in part on retinoid signaling.\textsuperscript{11} RA enhances the transcription of the TG2 gene via GC box motifs in its promoter region through a physical interaction between newly synthesized RARs and preexisting Sp1.\textsuperscript{15} Therefore, the crosslinking and silencing of Sp1 by TG2 may be a feedback mechanism to control the excessive expression of TG2 and prevent it from playing Mr. Hyde.

Furthermore, TG2 contributes to the clearance of apoptotic cells by promoting monocyte infiltration via the dimerization of the monocyte chemotactic factor S19\textsuperscript{125} followed by macrophage engulfment via integrin β3,\textsuperscript{126} leading to inflammation suppression. In addition, TG2 contributes to wound repair and tissue stabilization via the crosslinking of various intracellular and extracellular proteins at inflammation sites.\textsuperscript{12} A peptide with anti-TG2 activity decreases lung inflammation accompanied by reduced neutrophil infiltration and cytokines expression.\textsuperscript{127}

However, TG2 has been reported to be anti-apoptotic, and the effect is linked to both its GTP binding and crosslinking activity.\textsuperscript{15,20} TG2-null mice do not exhibit an obvious hepatic phenotype defect but do exhibit an impaired clearance of apoptotic cells by phagocytosis under stress conditions and experience a more severe liver injury after CCL\textsubscript{4} or Fas administration.\textsuperscript{20,128} This discrepancy can be explained as follows. Sarang \textit{et al.}\textsuperscript{20} reported that TG2 protects against high-dose (1 μg/g body weight) Jo2 (anti-Fas antibody)-induced liver injury; TG2\textsuperscript{−/−} mice were more sensitive to Jo2-mediated necrosis than TG2\textsuperscript{+/+} animals. In those studies, Sarang \textit{et al.}\textsuperscript{20} used FVB mice as wild-type controls. We used wild-type littermates from heterozygous TG2\textsuperscript{+/−} mice used by Sarang \textit{et al.}\textsuperscript{20}; this treatment resulted in massive hepatic necrosis both in TG2\textsuperscript{+/−} and TG2\textsuperscript{−/−} mice. Thus, the varying genetic backgrounds of the TG2\textsuperscript{+/−} \textit{versus} TG2\textsuperscript{−/−} mice used by Sarang \textit{et al.}\textsuperscript{20} might have contributed to the discrepancy between their findings and ours. However, we reproduced the protective effect of TG2 silencing on hepatic injury with a low dose (0.1 μg/g body weight) of Jo2 using the exact same TG2\textsuperscript{−/−} mouse line used by Sarang \textit{et al.}\textsuperscript{20} Thus, TG2 may promote the hepatic apoptosis caused by relatively low doses (but not higher doses) of Jo2.

Using the same TG2\textsuperscript{−/−} mouse line used by Sarang \textit{et al.},\textsuperscript{20} Nardacci \textit{et al.}\textsuperscript{128} reported that TG2 is protective in CCl\textsubscript{4}-mediated liver injury and speculated that the observed increase in TG2 expression during the initial stages of liver fibrosis in HCV-infected patients may protect against liver injury. However, another explanation may be that high levels of TG2 contribute to liver injury in these patients; as we have shown in an animal model,\textsuperscript{12} TG2 inhibitors may be a useful treatment for the prevention of hepatic apoptosis.

### Table 6 Examples of opposing functions of TG2 in blood vessel formation

| Blood vessel | Reports | Possible causation | References |
|-------------|---------|--------------------|------------|
| Positive role | Formation and stability of blood vessels Migration and tubule formation of HUVEC Endothelial sprouting, migration of both endothelial and vascular mesenchymal cells, and organization of actin cytoskeleton Cell spreading and adhesion in the human endothelial cell line ECV304 Colocalization and binding with endostatin | Promotion of the angiogenic process in endothelial and mesenchymal cells Promotion of the angiogenic process via VEGF signals in endothelium TG2 inhibition results in reduced FN deposition, matrix-bound VEGFA, phosphorylation of VEGF receptor 2, and then suppresses migration and tubule formation | 161,162 30 164 |
| Negative role | Inhibition of angiogenesis and tumor growth via matrix changes through an intratumoral injection of TG2 into mice RA-mediated apoptosis in vascular smooth muscle cells | Adhesion activity with integrin or FN Promotion of angiogenesis via endostatin-TG2 binding Reduced organized vasculature via excess stabilization/accumulation of ECM crosslinking Effect in smooth muscle cells | 113,166 167,168 171 54 |
Fibrogenic Versus No or anti-Fibrogenic Functions of TG2

In injured liver cells, TG2 transforms into a crosslinking enzyme (open form) and contributes to the wound healing process and fibrosis (Table 3). First, the crosslinking reaction results in the formation of an N’-(γ-glutamyl)lysine isopeptide bond, which is one important step in the maturation or stabilization of ECMs (such as collagens) in the extracellular space, exacerbating hepatic fibrosis.117,118 The N’-(γ-glutamyl)lysine crosslink, which is undetectable in normal liver tissue, is present extracellularly in the fibrotic livers of patients with a variety of chronic liver diseases, primarily in inflammatory areas in which an intense remodeling is occurring.117 Second, this crosslinking ability of TG2 appears to have a crucial role in the fixation and activation of TGF-β,57 the most fibrogenic cytokine.130 TGF-β1 is released in a latent form (~300 kD) and converted to an active form of 25 kD. Enhanced TG2 activity is required in many tissues for this activation of TGF-β via its crosslinking of large latent complexes to the cell surface or to FN and other ECM components through a latent TGF-β-binding protein portion.

In addition to the liver, similar fibrogenic roles via the generation of TGFB have been reported in articular cartilage,59 kidney,61 lung,59 and pancreas.133 Third, in in vivo models of hepatic apoptosis and in ASH patients, Sp1 is crosslinked, oligomerized, and inactivated by nuclear TG2, leading to the activation of a caspase-independent apoptotic process resulting from the reduced expression of c-Met.12 The TG2-induced decrease in c-Met may be involved in the impaired hepatocyte regeneration observed in patients with alcoholic liver disease.13,134,135 Furthermore, Giebeler et al.136 reported that the downregulation of c-Met is associated with liver fibrosis, indicating a novel apoptotic axis accompanied by liver fibrosis, namely, a nuclear TG2/crosslinked Sp1/decline in c-Met. Supporting this hypothesis, the nuclear accumulation of TG2 and crosslinking of Sp1 are observed in the fibrotic area of patients with ASH.137

In summary, increased TG2 activity is associated with ECM production and TGF-β, as shown after chronic CCl4 intoxication in rats118 directly by stabilizing the ECM in an insoluble form and indirectly by promoting the generation of active TGF-β, which strongly enhances hepatic fibrogenesis by increasing ECM production. The reaction is Ca2+ dependent and is classically reported to be the biochemical basis for TG2 involvement in hepatic fibrosis.129 Therefore, amine substrates, such as putrescine and cystamine (competitive inhibitors of the crosslinking activity of the enzyme), have been shown to be protective in ethanol-induced liver injury as well as liver fibrosis induced by CCl4.138-140

In contrast, Popov et al.141 demonstrated no change in the extent of liver fibrosis after the treatment of TG2−/− mice with CCl4 or thioacetamide. Again, potential explanations for this discrepancy include differences in mouse background, the method used for TG2 gene targeting, and broad biological and non-specific activities of TG inhibitors.

Anti- Versus Pro-Apoptotic Roles of TG2 in Cancer Cells Partially Through the Regulation of Rb and E2F1 Activities

Multiple studies have shown elevated TG2 expression in many types of cancer cells9 to be associated with increased drug resistance, metastasis, and poor patient survival (Table 4).33,142 For example, an analysis of more than 30,000 genes from tumor samples revealed that TG2 is a highly expressed gene in pancreatic adenocarcinoma.143 An important property of the highly malignant tumor cells is their ability to survive in hostile host environments as they pass through the lymphatic system or the bloodstream in their attempt to colonize distant sites. TG2 stabilized contact points of tumor cells with the subendothelial matrix in free-floating melanoma cells isolated from arterioles.144 In contrast, the downregulation of TG2 expression in melanoma cancer cells promoted their ability to metastasize.145 The ectopic expression of TG2 in a highly malignant hamster fibrosarcoma cell line significantly reduces tumor incidence despite the fact that TG2-transfected clones exhibit no significant differences in growth rates, cell morphology, or levels of spontaneous apoptosis in vitro.146 This finding indicates a suppressive effect of TG2 on tumor growth and confirms the importance of TG2 in the phenotypic changes associated with cancer. Similar nuclear TG2-mediated cell death (as observed in ASH and NASH) has been found in the chemoprevention of cancer. Acyclic retinoid, a synthetic retinoid, stimulates the nuclear localization and activation of TG2,147 resulting in the crosslinking and inactivation of Sp1, thereby causing cell death in hepatocellular carcinoma cell lines through the downregulation of EGF receptors.79 In contrast, TG2 enhances EGF receptor expression in glioblastomas and then induces cell transformation.148 Therefore, a precise understanding of the expression and function of TG2 in the context of cancer stages and types is important for the implementation of TG2-based interventions to disrupt malignant invasion, growth, and survival.

In U937 human leukemic monocyte lymphoma cells undergoing apoptosis, nuclear TG2 polymerizes Rb protein, which culminates in the loss of anti-apoptotic action by Rb protein due to its interaction with E2F1 and the prevention of Rb degradation, which accelerates the degradation of E2F1 and leads to cell growth arrest/apoptosis.149 In contrast, in some cell lines (NIH3T3 mouse embryonic fibroblast cells, HL-60 human promyelocytic leukemia cells, and mouse embryonic lung fibroblasts) treated with RA or N-(4-hydroxyphenyl) retinamide, TG2 prolongs the anti-apoptotic action of Rb protein,150 protecting it from degradation by caspase-7 due to transamidation and/or the GTP-binding activities instead of undergoing polymerization. This conclusion has been drawn from the finding that monodansylcadaverine, a transamidation inhibitor, blocks the protective effect, whereas a transamidation-defective [C277V] TG2 mutant also exerts a protective effect.150 The latter is corroborated in HEK293 human embryonic kidney cells in which nuclear localization of the [C277S] TG2 mutant attenuates apoptosis due to its GTP binding or scaffold protein characteristics upon complexing with Rb protein.151 Furthermore, the phosphorylation of the Rb protein at Ser780 by TG2 destabilizes the Rb-E2F1 complex, ameliorating apoptosis in MCF-7 human breast carcinoma cells, which is further stimulated by the phosphorylation of TG2 with protein kinase A and abrogated by high Ca2+ concentrations.37 These observations indicate that in general, although the outcome differs depending on cell types and treatments, nuclear TG2 heavily polymerizes Rb protein under
extremely high Ca\textsuperscript{2+} concentrations, and low ATP concentrations, resulting in apoptosis through accelerating E2F1 degradation; otherwise, nuclear TG2 stabilizes Rb protein through the phosphorylation of Ser780 and the transamidation of certain glutamine residue(s) (but not through crosslinking) and preventing Rb degradation as a scaffold protein. This behavior indicates that intranuclear Ca\textsuperscript{2+} and GTP concentrations are important in determining whether TG2 acts as Dr. Jekyll or Mr. Hyde (opposing functions).\textsuperscript{16}

**Diabetes**

TG2 is involved in the membrane-mediated events required for glucose-stimulated insulin release from pancreatic β cells (Table 5).\textsuperscript{152–154} Vitamin A also induces insulin secretion from islets via TG2,\textsuperscript{155} and steroid hormone-induced TG2 facilitates the crosslinking of IGFBP1 and increases IGF-I actions.\textsuperscript{156} As a controversial effect, inhibitors of TG2, such as monodansylcadaverine and glycine methylester, do not prevent insulin secretion induced by either cAMP or phorbol ester at basal levels (10 nM) of Ca\textsuperscript{2+}; however, these inhibitors prevent insulin secretion induced by Ca\textsuperscript{2+}.\textsuperscript{157} These data indicate that the transamidation activity of TG2 has a critical role in insulin secretion.

TG2\textsuperscript{−/−} mice have impaired glucose-stimulated insulin secretion and show glucose intolerance after intraperitoneal glucose loading.\textsuperscript{158} The TG2\textsuperscript{−/−} mouse phenotype resembles that of maturity-onset diabetes in young patients who have several missense mutations located near the catalytic site of TG2 and impaired transamidation activity.\textsuperscript{158,159} However, TG2-disrupted mice and the constitutive transamidation active form of TG2-expressing mice show no significant differences in responses to a glucose or insulin challenge, suggesting that glucose homeostasis is TG2 independent.\textsuperscript{160}

**Blood Vessel Formation**

TG2 has a positive role in the formation and stability of blood vessels (Table 6).\textsuperscript{161,162} Coeliac disease-specific autoantibodies targeting TG2 disturb several steps of angiogenesis, including endothelial sprouting, the migration of both endothelial and vascular mesenchymal cells, ECM degradation, the organization of the actin cytoskeleton in capillary cell types, alterations of cell-ECM interactions to thereby affect endothelial cell adhesion, polarization, and motility.\textsuperscript{163–165} At the endothelium, TG2 co-localizes with integrin and has an important role in cell spreading and adhesion.\textsuperscript{113,166} Moreover, TG2 is co-localized with endostatin in the ECM secreted by endothelial cells under hypoxia, which stimulates angiogenesis and tumorigenesis.\textsuperscript{167,168} TG2 inhibition leads to a reduction in FN deposition and matrix-bound VEGFA in HUVECs; TG2 thus positively regulates angiogenesis in a VEGF-dependent manner.\textsuperscript{169} Microarray data show that TG2 is specifically upregulated by turbulent shear stress in coronary artery endothelial cells.\textsuperscript{170} Given the important role of shear stress in the development of atherosclerosis, we assert that TG2 regulates the progression of this disease. In an opposite effect, matrix changes induced by TG2 lead to the inhibition of angiogenesis and tumor growth,\textsuperscript{171} indicating that endothelial TG2 primarily promotes blood vessel formation via enhanced stabilization and migration of neovascularization; however, a part of extracellular TG2 reduces organized vasculature via the excess stabilization and accumulation of ECM following their crosslinking. In cultured endothelial cells, TG2 suppressed cell migration via the formation of TGF-β\textsuperscript{57} in vascular smooth muscle cells, TG2 is involved in the all-trans RA-mediated apoptosis and reduction of neointimal mass in balloon-injured blood vessels.\textsuperscript{58} More recently, TG2 was shown to block extracellular VEGF's binding to heparan sulfate proteoglycans and inhibit an early stage of angiogenesis.\textsuperscript{172}

Thus, the effect of TG2 on angiogenesis appears to differ depending on its stage and TG2's subcellular localization.

**Conclusions and Prospects**

The crosslinking activity of TG2 appears to represent the dominant function of TG2 during apoptotic cell death accompanied by an elevation of intracellular Ca\textsuperscript{2+}.\textsuperscript{15} In addition to crosslinking activity, at normal intracellular Ca\textsuperscript{2+} concentrations, the diverse cellular functions of TG2 appear to be attributed to Gh, PDI, and kinase activities. These various biochemical activities of TG2 are differentially regulated depending on its subcellular localization; they also determine whether TG2 has Dr. Jekyll or Mr. Hyde. In the outer membrane, TG2 is released from cells by an unknown mechanism and constitutively exhibits crosslinking activity for ECM and anchoring protein. In the intracellular membrane and cytosol, TG2 typically adopts a closed conformation with the binding of GTP but not that of Ca\textsuperscript{2+}, which contributes to intracellular Ca\textsuperscript{2+} homeostasis, cell proliferation, and other actions. Both growth-stimulating (anti-apoptotic) and pro-apoptotic functions of TG2 may depend on the cell type, the type of death stimuli, the intracellular localization of the enzyme and which of its activities are switched on.\textsuperscript{15}

Thus, the use of an existing inhibitor, such as cystamine, is not effective for the regulation of TG2-related pathogenesis. It is important to develop specific regulatory compounds against crosslinking, GTPase, FN-binding, PDI, the phosphorylation activities of TG2, and its cofactors. To control cell death and survival, we are now establishing and screening inhibitors that regulate the nuclear localization of TG2.

**Conflict of Interest**

The authors declare no conflict of interest.

**Acknowledgements**

Our experimental work referred to in this report was supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture (26860500, HT; 24500392, YF; 26292192, HK; 26102742, SK); Advanced Research Networks; and the Research on the Innovative Development and the Practical Application of New Drugs for Hepatitis B (Principal Investigator: SK) provided by the Agency for Medical Research and Development (AMED).

1. Fusus L, Picentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002; 27: 534–539.
2. Ixamaa SE, Mearns BM, Lorand L, Graham RM. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 2009; 89: 991–1023.
3. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003; 4: 140–156.
72. The biochemical mechanisms underlying these processes are complex and not yet fully understood. Further research is required to elucidate the precise roles of these enzymes in the various forms of cell death.

73. Studies have shown that calpain activity increases during apoptosis, and inhibitors of calpain can block the apoptotic process.

74. Calcium ions play a crucial role in regulating cell death by activating calpain and other proteases.

75. The role of caspases in apoptosis has been extensively studied, and their activation is considered a hallmark of apoptosis.

76. The balance between pro- and anti-apoptotic factors is critical in determining whether a cell will undergo apoptosis or survive.

77. Apoptosis is a complex process that involves multiple signaling pathways and regulatory mechanisms. Understanding these mechanisms will be essential for the development of new therapeutic strategies.

78. Cell death and disease series, Vol. 10, pp. 721-727, 2011.
116. Chen CS, Wu CH, Lee YC, Lee WS, Chen HM, Chen RJ et al. NF-kappaB-activated tissue transglutaminase is involved in ethanol-induced hepatic injury and the possible role of propolis in preventing fibrogenesis. Toxicology 2008; 246: 148–157.

117. Grenard P, Bresson-Hadni S, El Alaoui S, Chevalier V, Mutton DA, Ricard-Blum S. Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis. J Hepatol 2001; 36: 367–375.

118. Mizra A, Liu SL, Frizzell E, Zhu J, Maddakuri S, Martinez J et al. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am J Physiol 1997; 272: G281–G288.

119. Ulkami P, Harada M, Segel M, Torkkelta R, Graham RA, Kiohma C et al. Transglutaminase 2 regulates mallory body inclusion formation and injury-associated liver enlargement. Gastroenterology 2007; 132: 1515–1526.

120. Wu J, Liu SL, Zhu JL, Norton PA, Nojiri S, Hoek JB et al. Roles of tissue transglutaminase in ethanol-induced inhibition of hepatoцит proliferation and alpha 1-adrenergic signaling. J Biol Chem 2002; 277: 22215–22219.

121. D’Argenio G, Amoruso DC, Mazzone G, Vitaglione P, Romano A, Ribecco MT et al. Mesenchymal stem cells induce HSC differentiation through a TGF-beta-dependent mechanism. Exp Hematol 2002; 30: 254–262.

122. Tatsukawa H, Hirose S. Induction of cross-linking and silencing of Sp1 by transforming growth factor-2 in insulin-secreting cells. Exp Cell Res 1991; 195: 222–230.

123. Han JA, Park SC. Transglutaminase-dependent modulation of transcription factor Sp1. Mol Cells 2000; 10: 612–618.

124. Pascal E, Tjian R. Different activation domains of Sp1 govern formation of multimers and transactivation. Cell 1991; 67: 359–368.

125. Han JA, Park SC. Transglutaminase-dependent modulation of transcription factor Sp1. Mol Cells 2000; 10: 612–618.

126. Borowiak M, Garratt AN, Wustefeld T, Strehle M, Tautwein C, Birchmeier C. Met provides angiogenic stimuli and promotes metastasis. Cell 2010; 142: 372–384.

127. Sultana I, Gavagni MD, Pennington SH, Shi Y, Murray DJ, Muller L et al. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110Rb. J Biol Chem 2002; 277: 20127–20130.

128. MIalovikov T, Tucholski J, McCoy E, Johnson GV. Intracellular localization and activation state of tissue transglutaminase differentially impacts cell death. J Biol Chem 2004; 279: 8715–8722.

129. Bungay PJ, Owen RA, Coutts IC, Griffin M. A role for tissue transglutaminase in glucose-stimulated insulin release from the pancreatic beta-cell. Biochem J 1986; 235: 269–278.

130. Gomis R, Sener A, Malaïsse-Lagae F, Malaïsse WJ. Transglutaminase activity in pancreatic islets. Biochim Biophys Acta 1983; 760: 384–388.

131. Sener A, Dutton ME, Gomis R, Mathias PC, Malaïsse-Lagae F, Malaïsse WJ. Role of transglutaminase in insulin secretion by β-cells. J Biol Chem 2001; 276: 33343–33348.

132. Dardik HH, Adkins DK, Corter SE, Mathias KA, Sherrow BS. Vitamin A stimulation of insulin secretion: effects on tissue transglutaminase mRNA and activity using rat islets and insulin-secreting cells. Pancreas 1997; 16: 69–77.

133. Shibuya H, Sakai K, Kabi-Salmi M, Wachi Y, Ishihama M. Polymerization of insulin-like growth factor-binding protein-1 (IGFBP-1) potentiates IGF-I actions in placenta. J Cell Physiol 2011; 226: 434–439.

134. Lindsay MA, Bungay PJ, Griffin M. Transglutaminase involvement in the secretion of insulin from electroporinized rat islets of Langerhans. Biosci Rep 1990; 10: 557–561.

135. Bernassau, P. Federici M, Corasaniti M, Tornielli A, Belletti MA, De Laurenzo V et al. Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MOY tumor. FASEB J 2002; 16: 1371–1378.

136. Poroz O, Massa O, Cunzolo V, Colombro C, Maliponti B, Bertuzzi F et al. Missense mutations in the TG2 gene encoding transglutaminase 2 are found in patients with early-onset type 2 diabetes. Mutation in brief no. 982. Online. Hum Mutat 2007; 28: 1150.

137. Lissia SE, Apolin M, Holman S, Yi W, Jackson K, Buchfeldt JG et al. Glucose homeostasis in mice is transglutaminase 2 independent. PLoS One 2013; 8: e63246.

138. Burdik R, Inbal K. Complex formation between tissue transglutaminase II (TGT) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF. Exp Cell Res 2006; 312: 2973–2982.

139. Haron ZA, Hettasch JM, Lai TS, Dewhirst MW, Greenberg CS. Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J 2007; 21: 1231–1242.

140. Di Simone N, De Spriito M, Di Nicuolo F, Tersigni C, Castellani R, Silano M et al. Potential mechanisms of new platelate dysfunction in cellular disease: anti-transglutaminase antibodies impair human endothelial angiogenesis. Biochim Biophys Acta 2013; 1832: 88.

141. Myros E, Kaukinen K, Sotiropoulou M, Korponay-Szabo IR. Antithrombin III, the physiological inhibitor of tissue transglutaminase, is a potent inhibitor of tumor angiogenesis in vivo. J Cell Death 2006; 1: 1371–1378.

142. Jones RA, Nicholas B, Mian S, Davies PJ, Griffin M. Reduced expression of tissue transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MOY tumor. FASEB J 2002; 16: 1371–1378.

143. Lindsay MA, Bungay PJ, Griffin M. Transglutaminase involvement in the secretion of insulin from electroporinized rat islets of Langerhans. Biosci Rep 1990; 10: 557–561.

144. Bernassau, P. Federici M, Corasaniti M, Tornielli A, Belletti MA, De Laurenzo V et al. Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MOY tumor. FASEB J 2002; 16: 1371–1378.

145. Xu L, Hynes RO. GPR56 and TG2: possible roles in suppression of tumor growth by the glycoprotein VEGF. Am J Physiol 2003; 285: C1371–C1378.

146. Myros E, Kaukinen K, Sotiropoulou M, Korponay-Szabo IR. Antithrombin III, the physiological inhibitor of tissue transglutaminase, is a potent inhibitor of tumor angiogenesis in vivo. J Cell Death 2006; 1: 1371–1378.

147. Lindsay MA, Bungay PJ, Griffin M. Transglutaminase involvement in the secretion of insulin from electroporinized rat islets of Langerhans. Biosci Rep 1990; 10: 557–561.

148. Bernassau, P. Federici M, Corasaniti M, Tornielli A, Belletti MA, De Laurenzo V et al. Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MOY tumor. FASEB J 2002; 16: 1371–1378.

149. Di Simone N, De Spriito M, Di Nicuolo F, Tersigni C, Castellani R, Silano M et al. Potential mechanisms of new platelate dysfunction in cellular disease: anti-transglutaminase antibodies impair human endothelial angiogenesis. Biochim Biophys Acta 2013; 1832: 88.

150. Lindsay MA, Bungay PJ, Griffin M. Transglutaminase involvement in the secretion of insulin from electroporinized rat islets of Langerhans. Biosci Rep 1990; 10: 557–561.

151. Myros E, Kaukinen K, Sotiropoulou M, Korponay-Szabo IR. Antithrombin III, the physiological inhibitor of tissue transglutaminase, is a potent inhibitor of tumor angiogenesis in vivo. J Cell Death 2006; 1: 1371–1378.

152. Lindsay MA, Bungay PJ, Griffin M. Transglutaminase involvement in the secretion of insulin from electroporinized rat islets of Langerhans. Biosci Rep 1990; 10: 557–561.

153. Bernassau, P. Federici M, Corasaniti M, Tornielli A, Belletti MA, De Laurenzo V et al. Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MOY tumor. FASEB J 2002; 16: 1371–1378.

154. Di Simone N, De Spriito M, Di Nicuolo F, Tersigni C, Castellani R, Silano M et al. Potential mechanisms of new platelate dysfunction in cellular disease: anti-transglutaminase antibodies impair human endothelial angiogenesis. Biochim Biophys Acta 2013; 1832: 88.
173. Csomos K, Nemet I, Fesus L, Balajthy Z. Tissue transglutaminase contributes to the all-trans-retinoic acid-induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia. Blood 2010; 116: 3933–3943.

174. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 2010; 12: 863–875.

175. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002; 8: 143–149.

176. Zhai W, Jeong H, Cui L, Krainc D, Tjian R. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 2005; 123: 1241–1253.

177. D'Souza DR, Wei J, Shao Q, Hubert MD, Subramony SH, Vig PJ. Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 pathogenesis. Neurosci Lett 2006; 409: 5–9.

178. Kahlem P, Green H, Dijan P. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell 1998; 1: 595–601.

179. Grosso H, Woo JM, Lee KW, Im JY, Masliah E, Junn E et al. Transglutaminase 2 exacerbates alpha-synuclein toxicity in mice and yeast. FASEB J 2014; 28: 4280–4291.

180. Colak G, Johnson GV. Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia. Neurobioi Dia 2012; 45 1042–1050.